These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
63. Whole body FDG-PET for the evaluation and staging of small cell lung cancer: a preliminary study. Chin R; McCain TW; Miller AA; Dunagan DP; Acostamadiedo J; Douglas Case L; Harkness BA; Adler LP; Haponik EF Lung Cancer; 2002 Jul; 37(1):1-6. PubMed ID: 12057859 [TBL] [Abstract][Full Text] [Related]
64. The role of whole-body positron emission tomography with [18F]fluorodeoxyglucose in identifying operable colorectal cancer metastases to the liver. Lai DT; Fulham M; Stephen MS; Chu KM; Solomon M; Thompson JF; Sheldon DM; Storey DW Arch Surg; 1996 Jul; 131(7):703-7. PubMed ID: 8678767 [TBL] [Abstract][Full Text] [Related]
65. Occult primary tumors of the head and neck: lack of benefit from positron emission tomography imaging with 2-[F-18]fluoro-2-deoxy-D-glucose. Greven KM; Keyes JW; Williams DW; McGuirt WF; Joyce WT Cancer; 1999 Jul; 86(1):114-8. PubMed ID: 10391570 [TBL] [Abstract][Full Text] [Related]
66. 11C-Acetate can be used in place of 18F-fluorodeoxyglucose for positron emission tomography imaging of non-small cell lung cancer with higher sensitivity for well-differentiated adenocarcinoma. Nomori H; Shibata H; Uno K; Iyama K; Honda Y; Nakashima R; Sakaguchi K; Goya T; Takanami I; Koizumi K; Suzuki T; Kaji M; Horio H J Thorac Oncol; 2008 Dec; 3(12):1427-32. PubMed ID: 19057268 [TBL] [Abstract][Full Text] [Related]
67. [Positron emission tomography/computed tomography for lung cancer staging]. Ladrón de Guevara H D; Furnaro L F; Yévenes A S; Clavero R JM; Lazo P D; Rodríguez D P; Piottante B A; Pefaur D R; Pardo B C Rev Med Chil; 2015 Jan; 143(1):22-9. PubMed ID: 25860265 [TBL] [Abstract][Full Text] [Related]
68. Thoracic nodal staging with PET imaging with 18FDG in patients with bronchogenic carcinoma. Patz EF; Lowe VJ; Goodman PC; Herndon J Chest; 1995 Dec; 108(6):1617-21. PubMed ID: 7497771 [TBL] [Abstract][Full Text] [Related]
69. Accuracy and cost-effectiveness of [18F]-2-fluoro-deoxy-D-glucose-positron emission tomography scan in potentially resectable non-small cell lung cancer. Kelly RF; Tran T; Holmstrom A; Murar J; Segurola RJ Chest; 2004 Apr; 125(4):1413-23. PubMed ID: 15078754 [TBL] [Abstract][Full Text] [Related]
71. Satellite PET and lung cancer: a prospective study in surgical patients. Slosman DO; Spiliopoulos A; Couson F; Nicod L; Louis O; Lemoine R; Donath A; Junod AF Nucl Med Commun; 1993 Nov; 14(11):955-61. PubMed ID: 8290167 [TBL] [Abstract][Full Text] [Related]
72. [Impact of positron emission tomography on clinical management of potentially resectable non-small-cell lung cancer: a French prospective multicenter study]. Margery J; Milleron B; Vaylet F; Grahek D; Lebeau B; Mangiapan G; Bonardel G; de Labriolle-Vaylet C; Meignan M; Carette MF; Talbot JN; Housset B Rev Pneumol Clin; 2010 Oct; 66(5):313-20. PubMed ID: 21087727 [TBL] [Abstract][Full Text] [Related]
73. Usefulness 18F-FDG positron emission tomography/computed tomography for detecting recurrence of hepatocellular carcinoma in posttransplant patients. Kim YK; Lee KW; Cho SY; Han SS; Kim SH; Kim SK; Park SJ Liver Transpl; 2010 Jun; 16(6):767-72. PubMed ID: 20517911 [TBL] [Abstract][Full Text] [Related]
74. Value of F-18-fluorodeoxyglucose positron emission tomography after induction therapy of locally advanced bronchogenic carcinoma. Hellwig D; Graeter TP; Ukena D; Georg T; Kirsch CM; Schäfers HJ J Thorac Cardiovasc Surg; 2004 Dec; 128(6):892-9. PubMed ID: 15573074 [TBL] [Abstract][Full Text] [Related]
75. [Positron emission tomography of the thorax. The current clinical status]. Knopp MV; Bischoff H; Oberdorfer F; van Kaick G Radiologe; 1992 Jun; 32(6):290-5. PubMed ID: 1641486 [TBL] [Abstract][Full Text] [Related]